Taylor Wessing advises Paradigm Therapeutics Limited on its merger with Amedis Pharmaceuticals Limted

Taylor Wessing advises Paradigm Therapeutics Ltd on its merger with Amedis Pharmaceuticals Ltd, a medical chemistry and drug discovery company.

Taylor Wessing advises Paradigm Therapeutics Ltd on its merger with Amedis Pharmaceuticals Ltd, a medical chemistry and drug discovery company. At merger, the Company will have cash reserves of £11m, approximately half of which is new investment secured from existing investors on the back of the deal. The company will focus on identifying highly druggable targets and novel compounds in the areas of CNS, pain, endocrinology and metabolism.

Simon Walker, corporate partner at Taylor Wessing, comments:

"Taylor Wessing is delighted to have advised Paradigm Therapeutics Ltd on this exciting merger and follow on investment ".

In addition to Simon Walker, who led the transaction, other TW lawyers advising were David Mardle (corporate), Michelle Rodrigues (corporate), Malcolm Bates (IP/life sciences), Darren Bezzina (IP/life sciences), Charlie Pring (employment) and Lorraine McDonagh (real estate).

The investors were advised by Jones Day (Vica Irani) and Amedis Pharmaceuticals was advised by Hewitsons (James Lawrence).